These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20111599)

  • 1. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
    Vasan S; Schlesinger SJ; Chen Z; Hurley A; Lombardo A; Than S; Adesanya P; Bunce C; Boaz M; Boyle R; Sayeed E; Clark L; Dugin D; Boente-Carrera M; Schmidt C; Fang Q; LeiBa ; Huang Y; Zaharatos GJ; Gardiner DF; Caskey M; Seamons L; Ho M; Dally L; Smith C; Cox J; Gill D; Gilmour J; Keefer MC; Fast P; Ho DD
    PLoS One; 2010 Jan; 5(1):e8816. PubMed ID: 20111599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
    Vasan S; Schlesinger SJ; Huang Y; Hurley A; Lombardo A; Chen Z; Than S; Adesanya P; Bunce C; Boaz M; Boyle R; Sayeed E; Clark L; Dugin D; Schmidt C; Song Y; Seamons L; Dally L; Ho M; Smith C; Markowitz M; Cox J; Gill DK; Gilmour J; Keefer MC; Fast P; Ho DD
    PLoS One; 2010 Jan; 5(1):e8617. PubMed ID: 20111582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
    Currier JR; Ngauy V; de Souza MS; Ratto-Kim S; Cox JH; Polonis VR; Earl P; Moss B; Peel S; Slike B; Sriplienchan S; Thongcharoen P; Paris RM; Robb ML; Kim J; Michael NL; Marovich MA
    PLoS One; 2010 Nov; 5(11):e13983. PubMed ID: 21085591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
    Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.
    Chen Z; Huang Y; Zhao X; Ba L; Zhang W; Ho DD
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):412-21. PubMed ID: 18209682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
    García F; Bernaldo de Quirós JC; Gómez CE; Perdiguero B; Nájera JL; Jiménez V; García-Arriaza J; Guardo AC; Pérez I; Díaz-Brito V; Conde MS; González N; Alvarez A; Alcamí J; Jiménez JL; Pich J; Arnaiz JA; Maleno MJ; León A; Muñoz-Fernández MA; Liljeström P; Weber J; Pantaleo G; Gatell JM; Plana M; Esteban M
    Vaccine; 2011 Oct; 29(46):8309-16. PubMed ID: 21907749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
    Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
    PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
    Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
    Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
    Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
    Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
    PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
    Guardo AC; Gómez CE; Díaz-Brito V; Pich J; Arnaiz JA; Perdiguero B; García-Arriaza J; González N; Sorzano COS; Jiménez L; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; Alcamí J; Esteban M; López Bernaldo de Quirós JC; García F; Plana M;
    PLoS One; 2017; 12(10):e0186602. PubMed ID: 29065142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
    Baden LR; Walsh SR; Seaman MS; Cohen YZ; Johnson JA; Licona JH; Filter RD; Kleinjan JA; Gothing JA; Jennings J; Peter L; Nkolola J; Abbink P; Borducchi EN; Kirilova M; Stephenson KE; Pegu P; Eller MA; Trinh HV; Rao M; Ake JA; Sarnecki M; Nijs S; Callewaert K; Schuitemaker H; Hendriks J; Pau MG; Tomaka F; Korber BT; Alter G; Dolin R; Earl PL; Moss B; Michael NL; Robb ML; Barouch DH;
    J Infect Dis; 2018 Jul; 218(4):633-644. PubMed ID: 29669026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
    Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
    PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
    Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
    Hayton EJ; Rose A; Ibrahimsa U; Del Sorbo M; Capone S; Crook A; Black AP; Dorrell L; Hanke T
    PLoS One; 2014; 9(7):e101591. PubMed ID: 25007091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
    Mehendale S; Thakar M; Sahay S; Kumar M; Shete A; Sathyamurthi P; Verma A; Kurle S; Shrotri A; Gilmour J; Goyal R; Dally L; Sayeed E; Zachariah D; Ackland J; Kochhar S; Cox JH; Excler JL; Kumaraswami V; Paranjape R; Ramanathan VD
    PLoS One; 2013; 8(2):e55831. PubMed ID: 23418465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
    Hayes P; Gilmour J; von Lieven A; Gill D; Clark L; Kopycinski J; Cheeseman H; Chung A; Alter G; Dally L; Zachariah D; Lombardo A; Ackland J; Sayeed E; Jackson A; Boffito M; Gazzard B; Fast PE; Cox JH; Laufer D
    Clin Vaccine Immunol; 2013 Mar; 20(3):397-408. PubMed ID: 23345581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
    Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
    J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
    Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
    J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.